Matrix Metalloproteinase 3
"Matrix Metalloproteinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An extracellular endopeptidase of vertebrate tissues similar to MATRIX METALLOPROTEINASE 1. It digests PROTEOGLYCAN; FIBRONECTIN; COLLAGEN types III, IV, V, and IX, and activates procollagenase. (Enzyme Nomenclature, 1992)
| Descriptor ID |
D019278
|
| MeSH Number(s) |
D08.811.277.656.300.480.525.700.200 D08.811.277.656.675.374.525.700.200 D12.644.276.848.200 D12.776.467.836.200
|
| Concept/Terms |
Matrix Metalloproteinase 3- Matrix Metalloproteinase 3
- Metalloproteinase 3, Matrix
- Transin
- MMP3 Metalloproteinase
- Metalloproteinase, MMP3
- Stromelysin 1
- MMP-3 Metalloproteinase
- MMP 3 Metalloproteinase
- Metalloproteinase, MMP-3
- Stromelysin
|
Below are MeSH descriptors whose meaning is more general than "Matrix Metalloproteinase 3".
Below are MeSH descriptors whose meaning is more specific than "Matrix Metalloproteinase 3".
This graph shows the total number of publications written about "Matrix Metalloproteinase 3" by people in this website by year, and whether "Matrix Metalloproteinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Matrix Metalloproteinase 3" by people in Profiles.
-
Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1). Front Immunol. 2021; 12:593595.
-
Pharmacological Inhibition of MMP3 as a Potential Therapeutic Option for COVID-19 Associated Acute Respiratory Distress Syndrome. Infect Disord Drug Targets. 2021; 21(6):e170721187996.
-
Matrix metalloproteinase 3 as a valuable marker for patients with COVID-19. J Med Virol. 2021 01; 93(1):528-532.
-
Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. Inflamm Bowel Dis. 2020 04 11; 26(5):756-763.
-
Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. IUBMB Life. 2019 07; 71(7):969-977.
-
Follistatin-like protein 1 induction of matrix metalloproteinase 1, 3 and 13 gene expression in rheumatoid arthritis synoviocytes requires MAPK, JAK/STAT3 and NF-?B pathways. J Cell Physiol. 2018 01; 234(1):454-463.
-
Asporin-deficient mice have tougher skin and altered skin glycosaminoglycan content and structure. PLoS One. 2017; 12(8):e0184028.
-
Biomarkers, imaging and disease activity indices in patients with early axial spondyloarthritis: the Italian arm of the SpondyloArthritis-Caught-Early (SPACE) Study. Reumatismo. 2017 Aug 03; 69(2):65-74.
-
Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Angiology. 2017 Nov; 68(10):850-862.
-
Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. Clin Nephrol. 2016 Jan; 85(1):44-54.